



The Pharmacy
Guild of Australia

NSW Branch

COMMUNITY PHARMACY & THE NEEDLE SYRINGE PROGRAM (NSP)

Christina Cho
Guild Clinical Education Co-Ordinator

Harm Minimisation

- Does not condemn or condone drug use
- **AIM:** Reduce associated harms to the individual and the community

WHY NSPs?

- Originally funded to reduce the transmission of HIV amongst PWID and the wider community



1982:
First case
of AIDS
diagnosed
in St
Vincent's
Hospital

1984:
400
people
diagnosed
with HIV

1986:
NSP
piloted at
St
Vincent's
(illegally)

1987:
2400
people
diagnosed
with HIV
and NSP
is adopted

1989:
1600
people
diagnosed
with HIV


2015:
1025
people
diagnosed
with HIV



Statistics

- 800 NSPs across Australia
 - 525 in NSW
- 30 million needles and syringes annually
- Estimated: population of 89,000 – 205,000
- *2000-2009: 32,050 cases of HIV prevented*

(2014) HIV rates globally





The Needle and Syringe Program

AIM: To reduce the transmission of BBVs among PWIDs

OBJECTIVE: To minimise risk behaviours that have the potential to transmit BBVs

Additional benefits:

- Reduction in other injecting related injuries
- Less difficulty/pain injecting
- Provides support and access to healthcare for many marginalised clients



Australian results : NSP

Financial: an outlay of \$243 million on NSP initiatives resulted in a net financial cost saving of \$1.03 billion

Quality and quantity of life benefits (2010):

- 650 fewer people living with cirrhosis
- 90 Hep-C related deaths prevented
- 4,500 AIDS-related deaths prevented



Pharmacy Fitpack Scheme:

Via Pharmaceutical
wholesaler at no
charge

If wholesaler is out
of stock, PGA can
be contacted to
assist in supplies

Prices in community
pharmacy average
around \$3.30 per
pack

When fitpack is
exchanged = FREE

Upon initial
registration into the
program = \$385
(GST included)

Charge per initial
fitpack to customer
is pharmacy's
decision



The Pharmacy
Guild of Australia
NSW Branch

The PGA and NSP:

To register for the NSP (initial registration)

Change to pharmacy details

Online request form to be completed

Difficulties purchasing Fitpacks from wholesaler

Access to educational material and/or resources

HOME > GUILD BRANCHES > NSW > PROFESSIONAL SERVICES > NEEDLE & SYRINGE PROGRAM

NSW Pharmacy Needle and Syringe Program

The Needle and Syringe Program is an evidence-based public health program, which aims to minimise the transmission of blood borne viruses amongst people who inject drugs.

Pharmacy Needle and Syringe Program (PNSP) outlets are key contributors to Australia's network of Needle and Syringe Program services, with community pharmacies representing over 50% of the needle and syringe program outlets located in the community. The community pharmacy network is well placed to provide assistance in the distribution of sterile injecting equipment, advice, and referral to treatment services.

The PNSP is fully funded by the NSW Ministry of Health and is administered by The Pharmacy Guild of Australia (NSW Branch).



REGISTER TO PARTICIPATE



UPDATE YOUR PHARMACY
DETAILS



INFORMATION: PROGRAM
INCENTIVES





The Pharmacy
Guild of Australia

NSW Branch

Questions? Enquiries?

- **Health Services**

02 9467 7100

healthservices@nsw.guild.org.au

- **Guild Clinical**

02 9467 7156

Guild.clinical@nsw.guild.org.au

HIV & Viral Hepatitis

2018

Rosie Gilliver

Clinical Nurse Consultant- KRC




Health
South Eastern Sydney
Local Health District

Objectives

- To recognise who might be at risk of HIV and viral hepatitis
- To understand the basic epidemiology and biology of HIV and viral hepatitis
- To understand the benefits of identification and treatment of HIV and viral hepatitis
- To know how to reduce the risk of transmission of HIV and viral hepatitis
- To know where to refer for testing and treatment
- To understand the impact of NSPs on HIV and viral hepatitis transmission

HIV

- HIV = Human Immunodeficiency Virus
- AIDS = Acquired Immunodeficiency Syndrome



NSW HIV STRATEGY 2016-2020

$$[\text{TEST OFTEN}] + [\text{TREAT EARLY}] + [\text{PREVENT}] = \text{ENDING HIV 2020}$$



TEST MORE

Together we can make it happen.

$$[\text{TEST MORE}] + [\text{TREAT EARLY}] + [\text{STAY SAFE}] = \text{ENDING HIV}$$

[CLICK HERE FOR TEST LOCATIONS](#)

OUR PRIORITY POPULATIONS



People with HIV



Gay and homosexually active men



Aboriginal people



Sex workers



People who inject drugs



People from culturally and linguistically diverse backgrounds

OUR PRIORITY SETTINGS



Publicly funded HIV and sexual health services



Community



General practice and primary health care



Aboriginal Community Controlled Health Services



NSW Needle and syringe program outlets



Antenatal care



Drug and alcohol services



Mental health services



Emergency departments

NSW HIV strategy 2016-20

To virtually eliminate HIV transmission in NSW by 2020

and to

Sustain the virtual elimination of HIV transmission in people who inject drugs, sex workers and from mother-to-child

Sustain the central role of condoms in preventing the transmission of HIV

Reduce sharing of injecting equipment among people who inject drugs by 25%

Assess all people attending public sexual health services and high caseload general practices for PrEP eligibility

Facilitate testing of all recent sexual and injecting partners of people newly diagnosed with HIV


Increase the frequency of HIV testing in priority populations in accordance with risk

Strengthen service integration and models of care to deliver HIV testing in our priority settings

Strengthen systems and service integration for HIV prevention, diagnosis and management for Aboriginal people at risk

Increase the proportion of people with diagnosed HIV on ART to 95%


Newly diagnosed HIV infections in Australia, 1984-2017



* Total includes transgender people and people for whom data on sex was missing.

Source: State and territory health authorities; see Methodology for detail.

Figure 1.1.20 Newly diagnosed HIV and HIV exposure category, 2013–2017, by Aboriginal and Torres Strait Islander status



Note: Percentages may not add to 100% due to rounding

Source: State and territory health authorities; see Methodology for detail.

Acute HIV

- 2-6 weeks post exposure
- Known as 'seroconversion illness'
- Occurs in 50-90% cases
- Fever, pharyngitis, lymphadenopathy, rash, splenomegaly, meningitis
- Many have no symptoms
- Patients will have a high viral load and may have a low CD4 (T cell) count
- Highly infectious at this time
- Window period= may not show up in blood tests



Chronic HIV

- Normal or reduced CD4 count
- Variable viral loads ('set point')
- Symptoms may include fatigue, night sweats, lymphadenopathy
- Immunosuppression (CD4 < 200)
- Opportunistic infections
- Malignancies

HIV transmission

- Occurs via blood and body secretions
- Risk is increased by other STIs, viral load and genetic factors
- Risk is reduced by condoms



Exposure & Transmission Risk

(source known HIV +ve)

- Receptive anal: 1/70 (ejac), 1/155 (no ejac)
- Receptive vaginal: 1/1250
- Insertive anal: circ- 1/900 uncirc, 1/160
- Insertive vaginal: 1/2500
- HIV not transmitted via kissing, saliva, urine.

Source: National PEP Guidelines- ASHM 2016.

HIV seroprevalence in Australia

- Homosexual men (Sydney) 10%
- Injecting drug users < 1.0% (heterosexual)
- Sex workers (Australia born) 0.1%
- Consider country of origin, and travel overseas
- Prevalence in Aboriginal population is similar even though incidence is now higher, so definitely **not** considered a risk group for sexual contact

Blood exposure

- Risk increased by volume of blood, viral load of source, type of injury
- Needle-stick injury to Health Care Worker - 1/333
- Use of contaminated injecting equipment - 1/125

Vertical transmission

- Transmission from mother to child
 - risk 15-40%
- Reduced by initiation of maternal medication and treatment during labour
 - risk reduced to less than 1%
- Universal testing?




HIV treatments



- HAART (Highly Active Antiretroviral Therapy)
- Consists of a combination of usually three drugs
- Proven that HIV treatment should not be delayed once patient is ready. Many people now start at time, or close to diagnosis
- Early treatment has personal benefit (START study), but also public health benefit in terms of reducing the possibility of onwards transmission (HPTN 052)
- Provided at
 - Sexual health services (free tests and consults)
 - Some GPs (need ASHM s100 course)
 - Hospital infectious disease/Immunology
 - Sexual health services can support medicare ineligible

HIV treatments *con't*



- Target lifecycle of HIV (reverse transcription, integration, protein cleavage)
- Aim of treatment is to reduce viral load to an undetectable level so immune system (CD4) can recover
- People with undetectable VL are not able to transmit virus
- Not curative.. Virus rebounds if treatment stops
- May have side effects and toxicities.. Newer drugs better
- Needs strict adherence for effectiveness (90% best)
- But may afford almost normal life expectancy

HIV treatments:

- Several Single Tablet Regimens “STRs”
- Guidelines recommend Integrase based therapy first line
 - Triumeq, Genvoya, Descovy/raltegravir
 - Darunavir or rilpivirine combinations ins specific situations
- Australia follows USA guidelines
- Drug interactions important (booster)
- Most drugs tolerable
 - Nausea, GI upset, headache, dysphoria, rash (rare)

Rilpivirine/tenofovir alafenamide/emtricitabine	<i>Odefsey</i>	
Elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide	<i>Genvoya</i>	
Elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil	<i>Stribild</i>	
Dolutegravir/ abacavir/ lamivudine	<i>Triumeq</i>	
Darunavir/cobicistat/ emtricitabine/ tenofovir alafenamide	<i>Symtuza</i>	

HIV prevention

- Encourage safer sex
- Encourage use of clean injecting equipment (HIV prevalence < 1% in Aust because of NSP)
- Treatment as prevention
- Regular testing- KRC/C180, GP, SHS
- Pre-Exposure prophylaxis- PrEP- at clinics

HIV Pre-exposure prophylaxis: PrEP

Secure | <https://epic-nswstudy.org.au>

EPIC-NSW

Home About PrEP About EPIC-NSW Join the Study Study Team News
For Clinicians Contact us

EPIC-NSW is here

PrEP is a new way for people to protect themselves from HIV.

EPIC-NSW (Expanded PrEP Implementation in Communities in NSW) is bringing PrEP to people at high risk of HIV infection in NSW. EPIC-NSW is enrolling now.





Figure 1: Overall cumulative enrolment



Who?

High risk gay men (unprotected sex/STIs/meth)

- One tablet once a day (Truvada – Emtricitabine/Tenofovir Tablets)
- Some people may take it intermittently

Others if at risk sexually and high risk (partner positive not on treatment)

Now on PBS for high or medium risk people.. Transitioning from EPIC to GPs... all GPs can prescribe

HIV testing and referral

- Sexual health clinics- e.g Kirketon Road/SSHC
- GPs- s100 – shared care promoted through ASHM
- Community testing underway for gay men- aTEST-KX
- Rapid testing available in NSW- MSM or high risk




<http://www.acon.org.au/hiv/where-to-get-tested>

[THE TEST](#)[THE RESULTS](#)[PRIVACY](#)[CONSENT WITHDRAWAL](#)[NEED HELP?](#)


DO YOU NEED A HIV TEST?

The answer is yes. HIV is now a treatable health condition. The first step to living a healthy life with HIV is to get tested. The Dried Blood Spot (DBS) HIV test is a new, free, easy, private and accurate way to test for HIV. It involves a few drops of blood that you collect from yourself at home. You return the DBS HIV test to us in a reply paid envelope and receive the result by phone, text or email. You don't need to go to a clinic or a doctor to do this test.

www.hivtest.health.nsw.gov.au



Hepatitis



What is Hepatitis?

- Hepatitis indicates inflammation of the liver
- Most cases are caused by viruses such as HAV, HBV and HCV
- Other causes include other infectious agents, drugs or autoimmune disease

Signs and Symptoms

Acute Hepatitis

- Nausea, vomiting, anorexia, lethargy, jaundice
- Dark urine
- Tender, enlarged liver
- Less than 1% of cases develop acute liver failure



Chronic Hepatitis

- Often asymptomatic
- Early symptoms/disease: tiredness, anorexia, nausea, RUQ discomfort
- Progressive liver disease: peripheral stigmata e.g. spider naevi, palmar erythema
- Advanced liver disease: portal hypertension with ascites, oesophageal varices
- Ankle /abdo swelling
- Easy bruising
- HCC (Hepatocellular carcinoma)

Hepatitis A & B- vaccination

- Effective vaccines for both A&B
- Should screen PWID, CALD, Aboriginal, MSM, sex workers
- Separate vaccines, or combined in Twinrix
- Australian Immunisation Handbook
- NSP also prevents HBV




Hepatitis B virus : HBV

DNA virus infecting hepatocytes


- 200,000 people with chronic HBV
- Symptoms – Acute hepatitis, most asymptomatic
- Transmitted: blood, body fluids
- 90% of adults clear, but 90% of neonates become chronic
- Chronic liver disease in 15-25% over time
- Vaccine effective- priority for prevention
- Treatment indicated in some situations- tenofovir/entacavir
- s100 community prescriber program for GPs- mentoring through ASHM



Geographic Distribution of Chronic HBV Infection



Natural History of Chronic HBV: The 4 Phases and Relevance to Treatment Decisions



IMMUNE TOLERANCE

High HBV DNA, Normal LFTs, HBeAg positive
 Monitor every 6-12 months

IMMUNE CLEARANCE

High HBV DNA, Abnormal LFTs, HBeAg positive
 At risk of progression to cirrhosis and HCC **therefore should be referred for consideration of treatment**

IMMUNE CONTROL

Low HBV DNA, Normal LFTs, HBeAg neg; anti-HBe pos
 Monitor every 6-12 months

IMMUNE ESCAPE

High HBV DNA, Abnormal LFTs, HBeAg neg; anti-HBe pos
 At risk of progression to cirrhosis and HCC **therefore should be referred for consideration of treatment**

Hepatitis C

- Most common viral hepatitis seen locally among PWID
- Spread: blood and vertical transmission
- Spread via sexual transmission less certain- cluster amongst HIV pos MSM
- Incubation: up to 6 months
 - For every 100 untreated patients:
 - 20 get cirrhosis
 - 5 get cancer
 - If left for 30+ years

NSW Hepatitis C Strategy 2014-2020

NSW HEALTH

HEPATITIS C STRATEGY 2014-2020

STRATEGY AT A GLANCE

GOALS



TO REDUCE HEPATITIS C INFECTIONS IN NSW



TO IMPROVE THE HEALTH OUTCOMES OF PEOPLE LIVING WITH HEPATITIS C IN NSW

TARGETS



REDUCE SHARING OF INJECTING EQUIPMENT AMONG PEOPLE WHO INJECT DRUGS BY 25%



INCREASE THE NUMBER OF PEOPLE ACCESSING HEPATITIS C TREATMENT IN NSW BY 100%*

* Over the life of this Strategy, a range of new drugs may become available that will change treatment and service delivery options. This target is subject to change accordingly.

ACTIONS



PREVENT:
Build on established hepatitis C prevention efforts

- Ensure the Needle and Syringe Program is meeting the needs of at-risk populations
- Continue to implement, and look for opportunities to enhance, drug and alcohol services and drug diversion programs
- Explore the use of notifications to better understand transmission, identify and investigate clusters and implement public health control measures where feasible
- Implement and evaluate other evidence-based prevention strategies

MANAGE:
Better management of hepatitis C

- Increase primary care, Aboriginal Community Controlled Health Services, correctional facilities and drug and alcohol treatment services offering testing, clinical management, treatment assessment and follow up among people from priority populations
- Support best practice management of hepatitis C and its complications
- Implement programs that support people to effectively manage their condition

TREAT:
Improve access to hepatitis C treatment

- Expand the number and types of services able to provide hepatitis C treatment
- Increase the proportion of clients treated through nurse-led and primary care models
- Prepare to deliver new hepatitis C treatment regimens on an expanded scale
- Support participation in clinical trials



SYSTEM ENABLERS

- Surveillance
- Performance monitoring and evaluation
- Clinical redesign and innovation
- Health systems and policy relevant research
- Workforce development
- Cultural competence
- Community engagement and partnerships
- Effective governance
- An evidence-informed population health approach



PRIORITY POPULATIONS

- People living with hepatitis C
- People who inject drugs, especially new initiates
- People in or recently in custodial settings
- Aboriginal people
- People from culturally and linguistically diverse backgrounds
- Young people who are at risk of injecting

Transmission

- Sharing injecting equipment
- Non-sterile tattooing or body-piercing
- Mother-to-child transmission (< 5% risk)
- Unsterile medical or dental procedures - particularly CALD background
- Infected blood or blood products (pre1990)
- ??? Sexual transmission - men who have sex with men (MSM)

Not transmitted by

- Sneezing, coughing
- Sharing food or drinks
- Mosquito bites
- Usually not transmitted by sex



NB: Avoid sharing household items such as razors
& toothbrushes

Hepatitis C virus: Clinical

- Acute Infection
 - < 5% have acute symptoms
- Chronic Infection
 - 75-80% people develop chronic infection and remain infectious
- **ALT elevation:** 6-7 weeks post exposure (as early as week 2)
- **HCV RNA in serum:** 1-3 weeks post exposure
- **Anti-HCV:** present in serum 20-150 days post exposure (mean 50 days)
- **Symptoms:** present at week 2-12

Diagnosis

- Anti-HCV IgG positive indicates exposure
- Raised ALT generally indicates liver inflammation
- Hepatitis C RNA positive indicates active and infectious disease state (as early as 6 weeks post exposure)
- Fibroscan shows how much liver damage has occurred
- Genotype helps choose drugs and length of treatment



Prevention


- Education
- Alternate routes of administration/OST
- Clean injecting equipment
- No current PEP or PrEP against HCV



How to decide who needs treatment?

- All people with Hep C should be offered treatment
- Can be done at KRC
 - Stage of liver disease (fibroscan)
 - Co-morbidities
 - Drug/Alcohol/mental/social
 - Readiness for treatment/Adherence
 - Clinical trials
- Those delaying therapy
 - Advice about reduction of progression
 - Regular follow-up and prepare the client for eventual treatment


The HCV diagnosis and care cascade, 2016-17



Adapted from Dore G, et al AVHC 2018

Number of prescriptions per month

Figure 9: Absolute frequency (A) and relative frequency (B) of prescriber types in each month for individuals initiating DAA treatment during March 2016 to March 2018 in Australia




Source https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-uptake-in-Australia_Iss9-JUL18.pdf


THE LATEST HEP C TREATMENTS

TALK TO YOUR DOCTOR, NURSE OR CLINIC ABOUT THE NEW CURES FOR HEP C


SOFOSBUVIR AND VELPATASVIR




SOFOSBUVIR AND LEDIPASVIR



GLECAPREVIR AND PIBRENTASVIR



GRAZOPREVIR AND ELBASVIR



WHO ARE THEY FOR? ADULTS WHO HAVE HEP C AND A MEDICARE CARD

[▲] MOST PEOPLE HAVE NO OR VERY MILD SIDE-EFFECTS ^{*} FOR A SMALL NUMBER OF PEOPLE, TREATMENT MAY LAST LONGER

IMPORTANT NOTE: TO MAKE SURE YOU ARE CURED, YOU NEED TO GET A PCR BLOOD TEST AT LEAST 12 WEEKS AFTER YOU FINISH YOUR TREATMENT.

Testing for Hepatitis C

- KRC/Sexual health/Primary care clinic
- GP practice
- Refer to those you come across into care
- Hepatitis NSW can assist with positive diagnoses

NUAA.org.au – peer-led support- workers

Hep.org.au – community based support resources


ashm.org.au health care provider resources

Importance of NSP


- IDUs, sex workers, MSM and ‘at-risk’ young people are commonly seen in NSP and outreach settings
- High risk for HIV and hepatitis
- Epidemics continue to be seen among these populations
- Transmission minimised by education from NSP workers
- Highly cost effective public health activity

15-20% report receptive sharing


Figure 28: Receptive Syringe Sharing in previous month in NSW, 2013 - 2016 (% , 95% CI)



Map 1.1: Global availability of needle and syringe programmes in the community and in prisons



Map 1.2: Global availability of opioid substitution therapy in the community and in prisons




Impact of Needle Syringe Programs

From 2000-10- 25,000 cases of HIV avoided by NSP (+90,000 HCV)

Reduction in incidence 30-70% from 2000-2010

1 dollar spent= 1.5-5.5 dollars saved (av. 4 \$)

Figure 4.2 Annual costs of treatment of diagnosed cases of HIV avoided by NSPs (Not discounted)





ANY
QUESTIONS
?

Rosie.Gilliver@health.nsw.gov.au



Health
South Eastern Sydney
Local Health District

Naloxone Developments

Rosie Gilliver Clinical Nurse Consultant

Kirketon Road Centre (KRC)




Health
South Eastern Sydney
Local Health District


Learning Objectives

- An overview of naloxone?
- ORTHN project, what is it and what does it mean for the rest of us?
- What's happening at KRC
- What can you do as community pharmacists?

Increasing OD Deaths in the last Decade




Age of opioid OD deaths is rising



Changing profile of all drug related deaths

Note, this data is for all drug related deaths, not just accidental overdose



What is an Opioid Overdose?

- Taking **more** of an opioid drug than the body can handle
- Opioid class drugs '**depress**' the respiratory system causing breathing to **slow down, become shallow and then stop altogether.**
 - The person may first 'go on the nod' or just 'drop', become unconscious, turn blue (due to lack of oxygen), and have a seizure.
 - The heart may then stop, leading to death.

Risk factors for opioid OVERDOSES

- **Mixing opioids with other sedating drugs:**
 - Alcohol, benzodiazepines, tricyclic antidepressants, anti-psychotics
- **Using again after a period of reduced tolerance - so after:**
 - hospital discharge
 - drug-free treatment (e.g. detox, rehab)
 - incarceration (prison, lock-up)
- **Injecting** instead of other routes (oral, snorted, smoked)
- **Using a greater amount** (or purity) of opioid than usual
- **Using alone** - no one able to call for help
- Having **other health problems** (e.g. major infection, fever, respiratory or liver disease, older age)
- Using in **unfamiliar places** (unknown dealer, drugs, location, people)

Consequences of Overdose

- Death
- Brain damage (cognitive impairment)
- Permanent muscle/nerve injury (fascial compartment syndrome)
- Kidney failure (due to rhabdomyolysis)
- Psychological trauma (witnessed or experienced)

Evidence-based interventions that reduce opioid Overdose deaths

1. Opioid substitution treatment
2. Supervised injecting rooms
3. ORTHN programs



HARM REDUCTION FOR PEOPLE WHO USE DRUGS

6	All people from key populations who inject drugs should have access to sterile injecting equipment through needle and syringe programmes .
7	All people from key populations who are dependent on opioids should be offered and have access to opioid substitution therapy .
8	All people from key populations with harmful alcohol or other substance use should have access to evidence-based interventions , including brief psychosocial interventions involving assessment, specific feedback and advice.
9	People likely to witness an opioid overdose should have access to naloxone and be instructed in its use for emergency management of suspected opioid overdose. NEW RECOMMENDATION

GUIDELINES



CONSOLIDATED GUIDELINES ON
**HIV PREVENTION,
DIAGNOSIS, TREATMENT
AND CARE FOR
KEY POPULATIONS**

JULY 2014

KEY POPULATIONS

- 20 years experience in >20 countries
- Large scale implementation in parts of USA, UK
- Since 2012 pilot projects commenced in several Australian states, now moving into ‘routine care’



Health
South Eastern Sydney
Local Health District

What is Naloxone?

Short acting opioid antagonist

— peak duration of action = 5-20 min

— half life 30-60 mins

- Naloxone 0.4mg ampoules or Prenoxad in 2 ml pre-loaded syringe for IM administration available on the PBS
- S3 medication can be prescribed by medical or nurse practitioner for take home supplies
- ‘Good Samaritan’ legislation applies in NSW
- Available over the counter at pharmacies
- Nyxoid[®] (intra-nasal naloxone) registered by the Therapeutic Goods Administration as a Schedule 3 medicine in September and anticipate it will be available in 2019 ? price



Costs

Cost of naloxone Ampoules

- Wholesale to LHD: approximately \$20 for 5 ampoules x 0.4mg each
- Community pharmacy between \$20-30 for 5 ampoules
- Overdose prevention kits made at KRC = Estimated \$10 / pack



Cost of Prenoxad

- Approximately \$40-60 for 2mg pre-filled syringe 5 x 0.4mg doses



The Overdose Response with Take Home Naloxone (ORTHN) Research project

- State wide translational research project involving 5 LHDs and 1 NGO
- SESLHD, Sydney LHD, HNE, SWSLHD, St Vincents, Murrumbidgee LHD and MSIC
- NUAA key partners
- Protocol included training & supply of naloxone by non-medical staff (e.g. nurses, NSP workers, social workers) under protocol
- Train the trainer model to credential staff
- Over 600 clients supplied with naloxone
- Evaluated highly by both staff and client perspectives

ORTHN

- Staff felt training suitable, demonstrated improved skills
- Training of clients took about 15 mins
- Clients demonstrated improved knowledge post training and confidence to use naloxone
- NUAA staff contacted subset clients post training
- High satisfaction, and 10% of clients had used naloxone since training
- Cost and ease of access was key component

**Narcan
Training
takes 10
minutes.**

**Got
time to
save a
life?**

Read a Paper
Take a Shower
Sing Bohemian Rhapsody
Eat a Burger
Brush the Dog
Pick your nose



Ten minutes is all it takes to get trained to use narcan & get a free take away that could save a mates life.

Ask How - Here & NOW!

@ KRC
Phone
9360 2766
4 more info



**SAVE LIVES?
BUT HOW??**



Next Session:

@ KRC Group Room - Session runs for approx. 1-2 hours

More information:

Speak to Rosie @ KRC Ph: 9360 2766

Where: Kirketon Road Centre (KRC),
Above the Darlinghurst Firestation,
CNR Victoria St & Darlinghurst Rd,
Kings Cross



What's happening @ KRC

In 2017, KRC received approval for nurse-initiated supply of naloxone, and KRC also participated in the Overdose Response and Take Home Naloxone (ORTHN) Program which crucially enabled credentialed non-medical health workers (e.g. health education officers, nurses, counsellors, NSP workers) to supply (THN)


- KRC has used these non-medical models in a variety of settings, where marginalised, often homeless, clients at high risk of overdose can be engaged

Results:


- THN delivered on 242 occasions to 211 clients during the 8 month study period. 78% initial, 22% replenishment (30/month)

- In the 8 months prior to non-medical supply THN was delivered on 95 occasions to 82 clients (12/month)


Who got it?



Where?



THN training delivered by:




Talking to someone about OD Management:

1. **Avoid** having an overdose
 - Know the risks & how to reduce them
2. **Assess** someone who has overdosed
 - Recognise the signs of an opioid overdose
3. **Treat** someone who has overdosed
 - Emergency response
 - When & how to use naloxone

What can you do?

1. Stock naloxone in your pharmacy
2. Promote the use of naloxone and encourage people who inject drugs or use prescribed opioids and their peers or family to carry it with them
3. Know where clients can access naloxone if they cannot afford to buy it (ie KRC, AOD services) or encourage them to get a script from their GP if they hold a healthcare card.



Thank you

Contact at the Kirketon Road Centre:

rosie.gilliver@health.nsw.gov.au

Phone: 02 9360 2766



Health
South Eastern Sydney
Local Health District